DELKENHEIM, Germany, May 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the company's schedule of key workshops and scientific presentations at the International Federation of Clinical Chemistry and Laboratory Medicine Congress (IFCC), May 15-19, in Berlin, Germany. The company will sponsor five scientific industry workshops covering a range of clinical diagnostic research in areas such as heart and renal disease, cancer, hepatitis, and vitamins D and active B12. The company also will present its total customer solution offering for Information Technology (IT), automation, e-learning and instrument demonstrations at the Abbott exhibit booth (Hall 13).
"As a global leader in diagnostics, Abbott is committed to scientific excellence and developing technologies and customer-focused solutions that enable laboratories to be more efficient and provide better clinical outcomes," said Brian Blaser, senior vice president, Diagnostics, Abbott. "The IFCC meeting will provide Abbott the platform to showcase many of the solutions we offer our customers to address the increasing demands on the lab."
Abbott's IFCC Workshops (all times are Central European) -------------------------------------------------------- -- Importance of Biomarkers in Optimizing the Treatment of Patients with Heart and Kidney Disease, May 16, 13:00 to 14:00 p.m., Hall 7 Nicolas Mills, M.D., Ph.D., a cardiologist at the British Heart Foundation Centre for Cardiovascular Science and Simon Walker, M.D., Ph.D., a senior lecturer and honorary consultant in Clinical Biochemistry in the Department of Clinical Biochemistry at Edinburgh University, will discuss their recently published research in the Journal of the American Medical Association (JAMA) demonstrating that for patients with suspected acute coronary syndrome (ACS), the use of more sensitive troponin assays can increase diagnosis of myocardial infarction (MI) by a third. The ARCHITECT Troponin assay can identify patients who would not have received treatment for myocardial infarction, but were at high risk of recurrent MI and death. Implementation of this assay and diagnostic reclassification of these patients was associated with improved clinical management, fewer death and fewer admissions with recurrent MI. Kai M. Schmidt-Ott, M.D., Charite Universitatsmedizin in Berlin, will also review results of a multi-center study in Europe and the United States of emergency department patients tested for neutrophil gelatinase-associated lipocalin (NGAL). The research showed that urine NGAL facilitates an early diagnosis of acute kidney injury (AKI) and can distinguish pre-renal from intrinsic acute kidney injury. AKI is a major cause of renal failure and must be diagnosed quickly to prevent kidney damage. Urine NGAL levels, alone or when combined with other clinical information, will be important for optimal patient management and for the development of novel therapeutic strategies based on an early detection of AKI. Per Venge, M.D., Ph.D., Head of the Department of Medical Sciences, Clinical Chemistry, University Hospital Uppsala in Sweden, will chair the workshop. -- Ovarian Cancer Biomarkers in the Clinical Context: Stratification and Monitoring, May 16, 16:45 to 17:45 h, Hall 7 Jalid Sehouli, M.D., from University Hospital Charite in Berlin, will discuss why an optimal referral of ovarian cancer patients based on their cancer risk can improve survival rates. Inga Laursen, M.D. from Statens Serum Institut in Copenhagen, will review a prospective study designed to validate the Risk of Ovarian Malignancy Algorithm (ROMA), a combined use of HE4 and another cancer marker, CA125, for identifying patients at risk for ovarian malignancies. Christian Marth, M.D., Medical University of Innsbruck, will discuss the role of the ovarian cancer biomarker CA125 in follow-up monitoring of patients. -- Laboratory Diagnosis of Hepatitis C: What Are We Looking For? May 17, 13:00 to 14:00 p.m., Hall 7 Jacques Izopet, Ph.D., PharmD, from the University of Toulouse, France will summarize current knowledge on HCV infections, especially in immunocompromised patients. Additionally, Paul Holder, MSc, clinical scientist at University College Dublin, will present data on the ARCHITECT HCV antigen assay, and its ability to detect cases missed by HCV-antibody tests alone. In Ireland, HCV Ag testing has recently been added to the set of markers used to test patients requiring regular hemodialysis and other high-risk groups to prevent infections in the antibody negative diagnostic window. Moreover, the assay is used to confirm an active disease in HCV antibody positive samples and can help to reduce costs for other confirmatory assays such as immunoblot assays. -- Automation and Workflow Improvement To Ensure Your Lab's Efficiency, May 17, 16:45 to 17:45 h, Hall 7 Matthias Orth, M.D., Marienhospital, Stuttgart, will provide an overview of the workflow and cost benefits of automated immunoassay systems. Mats Nybo, M.D. will discuss the implementation and adoption Abbott's Total Laboratory Automation System and how it increased efficiency and helped to deliver improvements and productivity for Odense Universiteshospital in Denmark. -- Vitamin D and B12: Immunoassays in Preventative Medicine, May 18, 13:00 to 14:00 h, Hall 7 Etienne Cavalier, Ph.D., University Hospital of Liege, Belgium, will review data on the performance of Abbott's ARCHITECT 25-OH Vitamin D Assay. The benefits of the Abbott test will be compared with other vitamin D test methods. Wolfgang Herrmann, M.D., Ph.D., Saarland University, Germany, will report data showing that a specific test for the biologically active form of B12 may provide earlier detection of individuals at risk for B12 deficiency. Abbott will also participate in an IFCC-sponsored workshop hosted by IFCC President Graham Beastall, Ph.D. about the value of laboratories and best practices. -- Adding Value to the Laboratory (IFCC-sponsored): May 19, 13:00-14:00 h, Hall 8 Sarah Jarvis, principal Clinical Biochemist at Wishaw General Hospital in NHS Lanarkshire, U.K., will host a discussion of best practices from the U.K. and highlight activities from National Pathology Week which promote the importance of laboratory professionals to the healthcare community. Dr. Graham Beastall, Ph.D. president of IFCC, will present on good practices among laboratories and the importance of lab professionals engaging with other health care practitioners to improve patient care.
About Abbott Diagnostics
Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 69,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.